Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 6/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23963986 | 1.00 | HDAC1 (0.43) | HDAC1HDAC2CDK9CCNT1NTRK1 | |
| SCHEMBL23933505 | 0.85 | HCRTR1 (0.41) | JAK1AURKAJAK2FLT3AURKB | |
| SCHEMBL23933503 | 0.85 | HCRTR1 (0.41) | JAK1AURKAJAK2FLT3AURKB | |
| SCHEMBL23933509 | 0.85 | HCRTR1 (0.41) | JAK1AURKAJAK2FLT3AURKB | |
| SCHEMBL25632552 | 0.82 | CHRM4 (0.56) | HDAC1HDAC2CDK9CCNT1NTRK1 | |
| SCHEMBL30403430 | 0.82 | CHRM4 (0.56) | HDAC1HDAC2CDK9CCNT1NTRK1 | |
| SCHEMBL23956976 | 0.82 | CHRM4 (0.56) | HDAC1HDAC2CDK9CCNT1NTRK1 | |
| SCHEMBL25625880 | 0.79 | NR1H2 (0.48) | JAK1AURKAJAK2FLT3AURKB | |
| SCHEMBL25271235 | 0.78 | CHRM2 (0.43) | JAK1AURKAJAK2FLT3AURKB | |
| SCHEMBL23963919 | 0.78 | CHRM2 (0.43) | JAK1AURKAJAK2FLT3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | HDAC1 742/4885HDAC2 1217/4885CDK9 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.